Rhone Poulenc Still Can't Get Any RespectGail Edmondson
Rhone-Poulenc chief Jean-Rene Fourtou wishes the market would give his company some credit. Fourtou has made huge strides in turning his $17 billion company into a global player in pharmaceuticals and chemicals. He has sold off commodity businesses and made $11 billion worth of acquisitions in pharmaceuticals, specialty chemicals, and agricultural products. In the latest deal, Rhone-Poulenc Rorer, a big U.S. drugmaker that is two-thirds owned by the French company, bagged British drugmaker Fisons PLC for $2.9 billion. The move boosts Rhone from 14th to 11th place in the global rankings of pharmaceutical companies.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- A L'Oreal Heiress Is Now the World's Richest Woman
- Ivanka Trump Faces Courtroom Showdown Over $785 Sandals
- How Electric Cars Can Create the Biggest Disruption Since the iPhone
- Uber Losing Battle in London After Regulator Revokes License
- A Storm's Never Destroyed a Grid Like Maria Ruined Puerto Rico's